Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $875.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target hoisted by Robert W. Baird from $761.00 to $875.00 in a research note issued to investors on Monday, Benzinga reports. The firm presently has a “neutral” rating on the biopharmaceutical company’s stock. Robert W. Baird‘s target price would indicate a potential downside of 5.70% from the stock’s previous close.

REGN has been the subject of several other research reports. Morgan Stanley increased their target price on shares of Regeneron Pharmaceuticals from $758.00 to $779.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 7th. Piper Sandler lifted their target price on Regeneron Pharmaceuticals from $854.00 to $865.00 and gave the company an “overweight” rating in a research report on Monday, October 19th. Guggenheim boosted their price target on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Canaccord Genuity Group boosted their target price on shares of Regeneron Pharmaceuticals from $875.00 to $922.00 and gave the stock a “buy” rating in a report on Wednesday, October 28th. Finally, Truist Financial boosted their price target on Regeneron Pharmaceuticals from $772.00 to $780.00 and gave the stock a “buy” rating in a research report on Wednesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $872.00.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $927.89 on Monday. The firm has a market cap of $95.54 billion, a price-to-earnings ratio of 20.49, a PEG ratio of 1.57 and a beta of 0.10. Regeneron Pharmaceuticals has a 12 month low of $591.52 and a 12 month high of $935.35. The company’s fifty day simple moving average is $793.30 and its 200 day simple moving average is $738.05. The company has a quick ratio of 3.66, a current ratio of 4.06 and a debt-to-equity ratio of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $16.51 by $3.56. The firm had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The company’s revenue for the quarter was up 36.3% on a year-over-year basis. During the same quarter last year, the business posted $11.83 EPS. As a group, research analysts forecast that Regeneron Pharmaceuticals will post 49.10 EPS for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In related news, EVP Marion Mccourt sold 1,131 shares of the company’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $857.39, for a total value of $969,708.09. Following the sale, the executive vice president owned 12,003 shares in the company, valued at $10,291,252.17. This represents a 8.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew J. Murphy sold 4,147 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total value of $3,204,386.90. Following the transaction, the insider directly owned 47,833 shares in the company, valued at approximately $36,960,559.10. The trade was a 7.98% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 8,093 shares of company stock valued at $6,506,845. 6.97% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of REGN. BlackRock Inc. bought a new position in shares of Regeneron Pharmaceuticals in the second quarter worth $5,682,636,000. Legal & General Group Plc purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth about $473,872,000. Bank of New York Mellon Corp purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth about $472,950,000. Deutsche Bank AG bought a new position in Regeneron Pharmaceuticals in the 2nd quarter worth about $323,249,000. Finally, Man Group plc bought a new position in Regeneron Pharmaceuticals in the 2nd quarter worth about $272,460,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.